All In Biotech

NDA 018938 · J Molner

Ddavp

Desmopressin Acetate · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Jul 21, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Mar 30, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

99

23 Phase 3, 8 recruiting

FAERS reports

3,313

2,397 serious, 238 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPONATREMIA Desmopressin acetate can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death [see Warnings and Precautions (5.1) ]. Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids [see Contraindications (4) and Warnings and Precautions (5.1) ]. Ensure the serum sodium concentration is normal before starting or resuming desmopressin acetate. Measure serum sodium within 7 days and approximately 1 month after initiating therapy, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia [see Dosage...

What it is approved for

From the label in effect Oct 24, 2025.

Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 ) Limitations of Use Desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. ( 1.3 ) von Willebrand’s disease (severe Type I) - not indicated for the treatment of patients with severe Type I von Willebrand’s disease and when there is evidence of an abnormal molecular form of factor VIII antigen. ( 1.3 ) 1.1 Central Diabetes Insipidus Desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Limitations of Use: Desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. 1.2 Hemophilia A Desmopressin acetate injection is indicated for patients with hemophilia A with factor VIII coagulant activity levels...

Mechanism: Desmopressin acetate increases plasma levels of factor VIII activity in patients with hemophilia and von Willebrand’s disease Type I. The antidiuretic effects of desmopressin acetate are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production. Desmopressin acetate is a replacement hormone for antidiuretic hormone in the treatment of central diabetes insipidus. The change in structure of arginine vasopressin to desmopressin acetate resulted in increased duration of action and a decreased vasopressor...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 30, 1984 Original approval · Type 3 - New Dosage Form · priority review
2 products under this application
  • DDAVP · DESMOPRESSIN ACETATE 0.004MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DDAVP · DESMOPRESSIN ACETATE 0.015MG/ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Desmopressin" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hyponatraemia339
  • drug ineffective221
  • headache191
  • nausea181
  • fatigue145
  • off label use143
  • vomiting138
  • dizziness117
  • diarrhoea110
  • pain105
  • asthenia98
  • malaise87

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200480
200563
200675
200748
2008143
2009147
2010141
2011138
2012167
2013100
2014135
2015133
2016183
2017173
2018166
2019144
2020152
2021172
2022196
2023189
2024255
2025195
2026118

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ddavp* (Desmopressin Acetate)

2024 spending

$348K

Beneficiaries

52

297 claims

Per beneficiary

$6,696

$10.04 per unit

View as table
YearSpending
2020$772,773
2021$599,706
2022$518,805
2023$420,012
2024$348,215

Part B: Ddavp* (Desmopressin Acetate*) · HCPCS J2597

2024 spending

$356K

Beneficiaries

2,151

2,468 claims

Per beneficiary

$165

2024 ASP limit $5.90 per unit

View as table
YearSpending
2020$535,096
2021$573,116
2022$461,489
2023$388,512
2024$355,880

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 683 on PubMed

Sponsor: J Molner

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.